Acurx New Antibiotic Achieves 94% Cure Rate Against C. Difficile, Outperforms Standard

Acurx Pharmaceuticals (NASDAQ: ACXP) announced the publication of Phase 2b clinical trial results for ibezapolstat (IBZ) in Lancet Microbe, showing superior efficacy in treating C. difficile infection (CDI) compared to standard treatment. The trial demonstrated 94% clinical cure rate with IBZ, with 100% of cured patients remaining recurrence-free after one month, versus 14% recurrence rate with vancomycin. IBZ also showed favorable effects on gut microbiome preservation. The drug has received FDA QIDP and Fast-Track Designation, plus EMA SME status. The company is now positioned to advance to Phase 3 international trials, supported by comprehensive data including chemistry, mechanism of action, and microbiological activity. This development is particularly significant as current treatments show lower cure rates and emerging antimicrobial resistance issues.

https://www.stocktitan.net/news/ACXP/acurx-announces-publication-in-lancet-microbe-of-phase-2b-clinical-hhwlwju5rqe2.html